Of note, the combination given as in the present study but with a different capecitabine regimen was recently evaluated in another single-arm, phase 2 feasibility study as adjuvant treatment in 77 patients with HER2-negative, oestrogen receptor-positive early-stage breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.